High-affinity binding of urocortin and astressin but not CRF to G protein-uncoupled CRFR1

Peptides

Volumn 20, Issue 11, 1999, Pages 1311-1319

  Rühmann, Andreas ^a,b   Bonk, Ines ^a   Köpke, Andreas K E ^a  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b Australian Nucl Sci Technol O   (Australia)

Author keywords

5' cyclic monophosphate); Astressin; cAMP (adenosine 3'; CD (circular dichroism); CRF (corticotropin releasing factor); CRFR1 (CRF receptor: type 1); G protein coupling; GTP S (guanosine 5' O (3 thiotriphosphate)); RPHPLC (reverse phase HPLC); Ucn (urocortin)

Indexed keywords

ASTRESSIN; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR DERIVATIVE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; NEUROPEPTIDE; UNCLASSIFIED DRUG; UROCORTIN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR BINDING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCULAR DICHROISM; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN BINDING; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SHEEP;

EID: 0344560606     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(99)00136-9     Document Type: Article

References (46)

1. Behan D.P., Grigoriadis D.E., Lovenberg T., Chalmers D., Heinrichs S., Liaw C., De Souza E.B. Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein implications for the treatment of CNS disorders . Mol Psychiatry. 1:1996;265-277.
2. Bergwitz C., Gardella T.J., Flannery M.R., Potts J.T. Jr, Kronenberg H.M., Goldring S.R., Jüppner H. Full activation of chimeric receptors by hybrids between parathyroid hormone and calcitonin. J Biol Chem. 271:1996;26469-26472.
3. Beyermann M., Fechner K., Furkert J., Krause E., Bienert M. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor. J Med Chem. 39:1996;3324-3330.
4. Chang C.P., Pearse R.V. II, O'Connell S., Rosenfeld M.G. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron. 11:1993;1187-1195.
5. Chen R., Lewis K.A., Perrin M.H., Vale W.W. Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA. 90:1993;8967-8971.
6. Chou P.Y., Fasman G.D. Conformational parameters for amino acids in helical, β-sheet, and random coil regions calculated from proteins. Biochemistry. 13:1974;211-245.
7. Dautzenberg F.M., Dietrich K., Palchaudhuri M.R., Spiess J. Identification of two corticotropin-releasing factor receptors from xenopus laevis with high ligand selectivity unusual pharmacology of the type 1 receptor . J Neurochem. 69:1997;1640-1649.
8. De Souza E.B., Perrin M.H., Whithouse P.J., Rivier J., Vale W.W., Kuhar M.J. Corticotropin-releasing factor receptors in human pituitary gland autoradiographic localization . Neuroendocrinol. 40:1985;419-422.
9. Donaldson C.J., Sutton S.W., Perrin M.H., Corrigan A.Z., Lewis K.A., Rivier J.E., Vaughan J.M., Vale W.W. Cloning and characterization of human urocortin. Endocrinology. 137:1996;2167-2170.
10. Fichtl B., Fülgraff G., Neumann H.G., Wollenberg P., Forth W., Henschler D., Rummel W. Wirkungen von Pharmaka auf den Organismus. Forth W., Henschler D., Rummel W., Starke K. Allgemeine und spezielle Pharmakologie und Toxikologie. 1996;18-21 Spektrum Akademischer Verlag, Heidelberg, Berlin, Oxford.
11. Gourlet P., Vilardaga J.P., De Neef P., Waelbroek M., Vandermeers A., Robberecht P. The C terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides. 17:1996;825-829.
12. Gulyas J., Rivier C., Perrin M., Koerber S.C., Sutton S., Corrigan A., Lahrichi S.L., Craig A.G., Vale W.W., Rivier J. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc Natl Acad Sci USA. 92:1995;10575-10579.
13. Hernandez J.F., Kornreich W., Rivier C., Miranda A., Yamamoto G., Andrews J., Tache Y., Vale W.W., Rivier J. Synthesis and relative potencies of new constrained CRF antagonists. J Med Chem. 36:1993;2860-2867.
14. Hoyer D., Boddecke H.W.G.M. Partial agonists, full agonists, antagonists dilemmas of definition . Trends Pharmacol Sci. 14:1993;270-275.
15. Iino K., Sasano H., Oki Y., Andoh N., Shin R.W., Kitamoto T., Totsune K., Takahashi K., Suzuki H., Nagura H., Yoshimi T. Urocortin expression in human pituitary gland and pituitary adenoma. J Clin Endocrin Metab. 82:1997;3842-3850.
16. Kenakin T. Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci. 18:1997;456-464.
17. Kishimoto T., Pearse R.V. II, Lin C.R., Rosenfeld M.G. A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci USA. 92:1995;1108-1112.
18. Kornreich W.D., Galyean R., Hernandez J.F., Craig A.G., Donaldson C.J., Yamamoto G., Rivier C., Vale W.W., Rivier J. Alanine series of ovine corticotropin releasing factor (oCRF) a structure-activity relationship study . J Med Chem. 35:1992;1870-1876.
19. Krause E., Beyermann M., Dathe M., Rothemund S., Bienert M. Location of an amphipathic α-helix in peptides by using reversed-phase HPLC retention behavior of D-amino acid analogs. Anal Chem. 67:1995;252-258.
20. Liaw C.W., Grigoriadis D.E., Lorang M.T., De Souza E.B., Maki R.A. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol Endocrinol. 11:1997;2048-2053.
21. Lovenberg T.W., Liaw C.W., Grigoriadis D.E., Clevenger W., Chalmers D.T., De Souza E.B., Oltersdorf T. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA. 92:1995;836-840.
22. Maguire M.E., Van Arsdale P.M., Gilman A.G. An agonist-specific effect of guanine-nucleotides on binding to the beta adrenergic receptor. Mol Pharmacol. 12:1976;335-339.
23. Miranda A., Koerber S.C., Gulyas J., Lahrichi S.L., Craig A.G., Corrigan A., Hagler A., Rivier C., Rivier J. Conformationally restricted competitive antagonists of human/rat corticotropin-releasing factor. J Med Chem. 37:1994;1450-1459.
24. Miranda A., Lahrichi S.L., Gulyas J., Koerber S.C., Craig A.G., Corrigan A., Rivier C., Vale W., Rivier J. Constrained corticotropin-releasing factor antagonists with i-(i+3) Glu-Lys bridges. J Med Chem. 40:1997;3651-3658.
25. Oki Y., Iwabuchi M., Masuzawa M., Watanabe F., Ozawa M., Iino K., Yoshimi T. Distribution and concentration of urocortin, and effect of adrenalectomy on its content in rat hypothalamus. Life Sci. 62:1998;807-812.
26. Pallai P.V., Mabilla M., Goodman M., Vale W.W., Rivier J. Structural homology of corticotropin-releasing factor, sauvagine, and urotensin I circular dichroism and prediction studies . Proc Natl Acad Sci USA. 80:1983;6770-6774.
27. Perrin M.H., Haas Y., Rivier J.E., Vale W.W. Corticotropin-releasing factor binding to the anterior pituitary receptor is modulated by divalent cations and guanyl nucleotides. Endocrinology. 118:1986;1171-1179.
28. Perrin M.H., Donaldson C.J., Chen R., Lewis K.A., Vale W.W. Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology. 133:1993;3058-3061.
29. Perrin M., Donaldson C., Chen R., Blount A., Berggren T., Bilezikjian L., Sawchenko P., Vale W.W. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci USA. 92:1995;2969-2973.
30. Perrin M.H., Sutton S., Bain D.L., Berggren W.T., Vale W.W. The first extracellular domain of corticotropin releasing factor-R1 contains major binding determinants for urocortin and astressin. Endocrinology. 139:1998;566-570.
31. Petraglia F., Florio P., Gallo R., Simoncini T., Saviozzi M., Di Blasio A.M., Vaughan J., Vale W.W. Human placenta and fetal membranes express human urocortin mRNA and peptide. J Clin Endocrin Metabol. 81:1996;3807-3810.
32. Provencher S.W. A constrained regularization method for inverting data represented by linear algebraic or integral equations. Comput Phys Commun. 27:1982;213-227.
33. Rivier J., Rivier C., Galyean R., Miranda A., Miller C., Craig A.G., Yamamoto G., Brown M., Vale W.W. Single point D-substituted corticotropin-releasing factor analogues effects on potency and physicochemical characterization . J Med Chem. 36:1993;2851-2859.
34. 1H NMR and distance geometry with restrained molecular dynamics. Protein Engineering. 6:1993;149-156.
35. Rühmann A., Köpke A.K.E., Dautzenberg F.M., Spiess J. Synthesis and characterization of a photoactivatable analog of corticotropin-releasing factor for specific receptor labeling. Proc Natl Acad Sci USA. 93:1996;10609-10613.
36. Rühmann A., Bonk I., Lin C.R., Rosenfeld M.G., Spiess J. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR) development of CRFR2β-selective antisauvagine-30 . Proc Natl Acad Sci USA. 95:1998;15264-15269.
37. Stenzel P., Kesterson R., Yeung W., Cone R.D., Rittenberg M.B., Stenzel-Poore M.P. Identification of a novel murine receptor for corticotropin-releasing hormone expressed in the heart. Mol Endocrinol. 9:1995;637-645.
38. Sydow S., Flaccus A., Fischer A., Spiess J. The role of the fourth extracellular domain of the rat corticotropin-releasing factor receptor type 1 in ligand binding. Eur J Biochem. 259:1999;55-62.
39. Turnbull A.V., Vaughan J., Rivier J.E., Vale W.W., Rivier C. Urocortin is not a significant regulator of intermittent electrofootshock-induced adrenocorticotropin secretion in the intact male rat. Endocrinology. 140:1999;71-78.
40. Valdenaire O., Giller T., Breu V., Gottowik J., Kilpatrick G. A new functional isoform of the human CRF2 receptor for corticotropin-releasing factor. Biochim Biophys Acta. 1352:1997;129-132.
41. Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science. 213:1981;1394-1397.
42. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S., Chan R., Turnbull A.V., Lovejoy D., Rivier C., Rivier J., Sawchenko P.E., Vale W.W. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature (London). 378:1995;287-292.
43. Vita N., Laurent P., Lefort S., Chalon P., Lelias J.M., Kaghad M., Le Fur G., Caput D., Ferrara P. Primary structure and functional expression of mouse and human brain corticotropin releasing factor receptors. FEBS Lett. 335:1993;1-5.
44. Wong M.L., Al-Shekhlee A., Bongiorno P.B., Esposito A., Khatri P., Sternberg E.M., Gold P.W., Licino J. Localization of urocortin messenger RNA in rat brain and pituitary. Mol Psychiatry. 1:1996;307-312.
45. Wulff B., Møller Knudsen S., Adelhorst K., Fahrenkrug J. The C terminal part of VIP is important for receptor binding and activation, as evidenced by chimeric constructs of VIP/secretin. FEBS Lett. 413:1997;405-408.
46. Yu J., Xie L.Y., Abou-Samra A.B. Molecular cloning of a type A chicken corticotropin-releasing factor receptor with high affinity for urotensin I. Endocrinology. 137:1996;192-197.